Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Global Price Controls Elimination May Not Affect U.S. Rx Costs – Economist

Executive Summary

Eliminating pharmaceutical price controls in foreign countries would result in more innovation, but not necessarily lower prices for U.S. consumers, American Enterprise Institute economist Kevin Hassett said during an International Trade Administration meeting Aug. 3

You may also be interested in...



Global Price Controls Cost Rx Industry $18-$27 Bil. A Year, Commerce Says

Global price controls cost pharmaceutical companies approximately $18 bil. to $27 bil. a year in lost revenue, the Commerce Department maintains in a Dec. 21 report to Congress entitled "Foreign Drug Price Controls: Their Effects on R&D, Innovation and Consumer Welfare.

Global Price Controls Cost Rx Industry $18-$27 Bil. A Year, Commerce Says

Global price controls cost pharmaceutical companies approximately $18 bil. to $27 bil. a year in lost revenue, the Commerce Department maintains in a Dec. 21 report to Congress entitled "Foreign Drug Price Controls: Their Effects on R&D, Innovation and Consumer Welfare.

House May Be Stopping Point For Rx Importation Bills, Hill Staffer Says

The House could be the last line of defense for blocking prescription drug importation legislation, rather than the Senate, a House subcommittee staffer said Nov. 17 at the Pharmaceutical Regulatory & Compliance Congress in Washington, D.C

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS044470

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel